Not available
Quote | Cerecor Inc. (NASDAQ:CERC)
Last: | $2.93 |
---|---|
Change Percent: | -1.68% |
Open: | $2.98 |
Close: | $2.93 |
High: | $2.98 |
Low: | $2.9 |
Volume: | 266,862 |
Last Trade Date Time: | 08/25/2021 04:41:35 am |
News | Cerecor Inc. (NASDAQ:CERC)
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeut...
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financ...
Message Board Posts | Cerecor Inc. (NASDAQ:CERC)
Subject | By | Source | When |
---|---|---|---|
New board is: https://investorshub.advfn.com/Avalo-Therapeutics-AVTX-40053/ | AliasUser1 | investorshub | 09/14/2021 10:00:46 PM |
$cerc Cerecor wins Fast Track Designation https://www.biospace.com/article/2021- | frankkruemmel | investorshub | 05/11/2021 4:41:12 PM |
And up 25% this morning | JohnLocke101 | investorshub | 05/11/2021 1:43:22 PM |
Biggest negative operating margin ever seen -706.02%, book | make it happen | investorshub | 05/11/2021 1:28:10 PM |
https://www.marketwatch.com/story/cerecors-investigational-covid-19-therapy-gets | frankkruemmel | investorshub | 05/11/2021 1:13:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeut...
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financ...
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-00...